# Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications

> **NCT00729703** · PHASE4 · COMPLETED · sponsor: **LivaNova** · enrollment: 462 (actual)

## Conditions studied

- Tachycardia

## Interventions

- **DEVICE:** Ovatio DR 6550
- **DEVICE:** OVATIO DR 6550

## Key facts

- **NCT ID:** NCT00729703
- **Lead sponsor:** LivaNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-12
- **Final completion:** 2013-10
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2015-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729703, "Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00729703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*